---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-23-000172"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2023-11-15T23:59:59+00:00"
generated_at: "2026-06-08T02:41:27.624424+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GRI Bio reports Q3 net loss $11M; cash $3.5M; IPF trial on track

## Summary
- Net loss $11.0M for 9 months ended Sep 30, 2023; R&D expenses $2.2M (vs $0.2M YoY) and G&A $7.2M (vs $0.4M YoY).
- Cash and equivalents $3.5M as of Sep 30, 2023.
- Phase 2a biomarker study of GRI-0621 for IPF on track to start before year-end 2023; interim data expected H1 2024.
- GRI-0803 SLE program on track for IND filing H1 2024; Phase 1a SAD topline data expected Q3 2024.
- Entered asset purchase agreement with Aardvark Therapeutics to sell legacy ADAIR assets and IP (no financial terms disclosed).

## SEC filing metadata
- accession: 0001824293-23-000172
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2023-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429323000172/0001824293-23-000172-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429323000172/val-20231115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-23-000172
- JSON: https://secwatch.observer/filing/0001824293-23-000172.json
- Plain text: https://secwatch.observer/filing/0001824293-23-000172.txt

## Key facts
- Earnings Releases
  GRI Bio, Inc. reported the quarter ended September 30, 2023 results: net income Net loss was $11.0 million for the nine months ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Net income: Net loss was $11.0 million for the nine months ended September 30, 2023
  - Result: reported results
  source text: GRI Bio, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2023, and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824293/000182429323000172/0001824293-23-000172-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.